BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 29750281)

  • 21. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
    Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
    J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ.
    Joo KM; Kim J; Jin J; Kim M; Seol HJ; Muradov J; Yang H; Choi YL; Park WY; Kong DS; Lee JI; Ko YH; Woo HG; Lee J; Kim S; Nam DH
    Cell Rep; 2013 Jan; 3(1):260-73. PubMed ID: 23333277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
    Almstedt E; Rosén E; Gloger M; Stockgard R; Hekmati N; Koltowska K; Krona C; Nelander S
    Neuro Oncol; 2022 May; 24(5):726-738. PubMed ID: 34919147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Assay for Profiling GBM Cancer Model Heterogeneity and Drug Screening.
    Stackhouse CT; Rowland JR; Shevin RS; Singh R; Gillespie GY; Willey CD
    Cells; 2019 Jul; 8(7):. PubMed ID: 31336733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of glioblastoma tumorspheres by combined treatment with 2-deoxyglucose and metformin.
    Kim EH; Lee JH; Oh Y; Koh I; Shim JK; Park J; Choi J; Yun M; Jeon JY; Huh YM; Chang JH; Kim SH; Kim KS; Cheong JH; Kim P; Kang SG
    Neuro Oncol; 2017 Feb; 19(2):197-207. PubMed ID: 27571886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
    Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
    Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy.
    Wilson KM; Mathews-Griner LA; Williamson T; Guha R; Chen L; Shinn P; McKnight C; Michael S; Klumpp-Thomas C; Binder ZA; Ferrer M; Gallia GL; Thomas CJ; Riggins GJ
    SLAS Technol; 2019 Feb; 24(1):28-40. PubMed ID: 30289729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A highly invasive human glioblastoma pre-clinical model for testing therapeutics.
    Xie Q; Thompson R; Hardy K; DeCamp L; Berghuis B; Sigler R; Knudsen B; Cottingham S; Zhao P; Dykema K; Cao B; Resau J; Hay R; Vande Woude GF
    J Transl Med; 2008 Dec; 6():77. PubMed ID: 19055779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.
    Nigim F; Cavanaugh J; Patel AP; Curry WT; Esaki S; Kasper EM; Chi AS; Louis DN; Martuza RL; Rabkin SD; Wakimoto H
    J Neuropathol Exp Neurol; 2015 Jul; 74(7):710-22. PubMed ID: 26083570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
    Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
    Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
    Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
    Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
    Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies.
    Kerstetter-Fogle AE; Harris PLR; Brady-Kalnay SM; Sloan AE
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calpain 2 is required for the invasion of glioblastoma cells in the zebrafish brain microenvironment.
    Lal S; La Du J; Tanguay RL; Greenwood JA
    J Neurosci Res; 2012 Apr; 90(4):769-81. PubMed ID: 22183788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orthotopic transplantation of retinoblastoma cells into vitreous cavity of zebrafish for screening of anticancer drugs.
    Jo DH; Son D; Na Y; Jang M; Choi JH; Kim JH; Yu YS; Seok SH; Kim JH
    Mol Cancer; 2013 Jul; 12():71. PubMed ID: 23835085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
    Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
    J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    Oudin A; Moreno-Sanchez PM; Baus V; Niclou SP; Golebiewska A
    BMC Cancer; 2024 Jan; 24(1):3. PubMed ID: 38166949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.
    Jandial R; Neman J; Lim PP; Tamae D; Kowolik CM; Wuenschell GE; Shuck SC; Ciminera AK; De Jesus LR; Ouyang C; Chen MY; Termini J
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.